A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: Analysis of sustained interferon γ production in a subset of patients

Clinical Cancer Research

Volumn 10, Issue 15, 2004, Pages 5027-5037

  Parihar, Robin ^a   Nadella, Padma ^a   Lewis, Adrian ^a   Jensen, Rhonda ^a   De Hoff, Carrie ^a   Dierksheide, Julie E ^a   VanBuskirk, Anne M ^a   Magro, Cynthia M ^a   Young, Donn C ^a   Shapiro, Charles L ^a   Carson III, William E ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 12; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOKINE; TRASTUZUMAB;

ADULT; AGED; ANEMIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTHRALGIA; ARTICLE; BLOOD LEVEL; BONE DISEASE; CANCER; CANCER CONTROL; CANCER IMMUNOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE STABILIZATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; GENETIC POLYMORPHISM; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; INNATE IMMUNITY; LEUKOPENIA; LYMPH NODE METASTASIS; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; NATURAL KILLER CELL; NAUSEA; NEUTROPENIA; OPTIMAL DRUG DOSE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CLINICAL TRIALS; COHORT STUDIES; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENOTYPE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERFERON TYPE II; INTERLEUKIN-12; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; MACROPHAGE INFLAMMATORY PROTEIN-1; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; POLYMORPHISM, GENETIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 4143149590     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0265     Document Type: Article

References (36)

1. Revillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998;34:791-808.
2. Tzahar E, Yarden Y. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochim Biophys Acta 1998;1377:M25-37.
3. Baselga J, Seidman AD, Rosen PP, Norton L. HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology (Huntingt) 1997;11:43-48.
4. Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992;89:4285-9.
5. Vogel C, Cobleigh MA, Tripathy D, et al. First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report. Eur J Cancer 2001;37 Suppl 1:S25-9.
6. Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001;19:2587-95.
7. Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:1800-8.
8. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
9. Baselga J, Albanell J. Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol 2001;12 Suppl 1:S35-41.
10. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:443-6.
11. Perussia B. Fc receptors on natural killer cells. Curr Top Microbiol Immunol 1998;230:63-88.
12. McKenzie SE, Schreiber AD. Fc gamma receptors in phagocytes. Curr Opin Hematol 1998;5:16-21.
13. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990;76:2421-38.
14. Fehniger TA, Shah MH, Turner MJ, et al. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol 1999;162:4511-20.
15. Carson WE, Parihar R, Lindemann MJ, et al. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol 2001;31:3016-25.
16. Parihar R, Dierksheide J, Hu Y, Carson WE. IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J Clin Investig 2002;110:983-92.
17. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002;20:3095-105.
18. Agarwala S, Kumar R, Bhatnagar V, Bajpai M, Gupta DK, Mitra DK. High incidence of adriamycin cardiotoxicity in children even at low cumulative doses: role of radionuclide cardiac angiography. J Pediatr Surg 2000;35:1786-9.
19. Gollob JA, Mier JW, Veenstra K, et al. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res 2000;6:1678-92.
20. Gollob JA, Veenstra KG, Parker RA, et al. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J Clin Oncol 2003;21:2564-73.
21. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
22. Bernard PS, Wittwer CT. Real-time PCR technology for cancer diagnostics. Clin Chem 2002;48:1178-85.
23. Chang JT, Chen IH, Liao CT, et al. A reverse transcription comparative real-time PCR method for quantitative detection of angiogenic growth factors in head and neck cancer patients. Clin Biochem 2002;35:591-6.
24. Fleming GF, Meropol NJ, Rosner GL, et al. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res 2002;8:3718-27.
25. Robertson MJ, Cameron C, Atkins MB, et al. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin Cancer Res 1999;5:9-16.
26. Gollob JA, Mier JW, Atkins MB. Clinical use of systemic IL-12 therapy. Cancer Chemother Biol Response Modif 2001;19:353-69.
27. Strieter RM, Polverini PJ, Arenberg DA, Kunkel SL. The role of CXC chemokines as regulators of angiogenesis. Shock 1995;4:155-60.
28. Bukowski RM, Rayman P, Molto L, et al. Interferon-gamma and CXC chemokine induction by interleukin 12 in renal cell carcinoma. Clin Cancer Res 1999;5:2780-9.
29. Pravica V, Asderakis A, Perrey C, Hajeer A, Sinnott PJ, Hutchinson IV. In vitro production of IFN-gamma correlates with CA repeat polymorphism in the human IFN-gamma gene. Eur J Immunogenet 1999;26:1-3.
30. Asderakis A, Sankaran D, Dyer P, et al. Association of polymorphisms in the human interferon-gamma and interleukin-10 gene with acute and chronic kidney transplant outcome: the cytokine effect on transplantation. Transplantation 2001;71:674-7.
31. Sparano JA. Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials. Semin Oncol 2001;28:20-7.
32. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
33. Rinehart J, Malspeis L, Young D, Neidhart J. Phase I/II trial of human recombinant beta-interferon serine in patients with renal cell carcinoma. Cancer Res 1986;46:5364-7.
34. Feldman ER, Creagan ET, Schaid DJ, Ahmann DL. Phase II trial of recombinant tumor necrosis factor in disseminated malignant melanoma. Am J. Clin Oncol 1992;15:256-9.
35. Repka T, Chiorean EG, Gay J, et al. Trastuzumab and Interleukin-2 in HER2-positive metastatic breast cancer: A pilot study. Clin Cancer Res 2003;9:2440-6.
36. Curcio C, Di Carlo E, Clynes R, et al. Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her2/neu carcinomas. J Clin Investig 2003;111:1161-70.